Overview
Postpartum amenorrhea-galactorrhea syndrome involves persistent lactation and absence of menstruation following childbirth, often due to elevated prolactin levels. Bromocriptine is used to manage this condition by reducing prolactin secretion and restoring reproductive function. 1Diagnosis
Persistent amenorrhea beyond 6 months postpartum
Excessive galactorrhea
Elevated prolactin levels (serum prolactin > 25 ng/mL)
Exclusion of other causes of amenorrhea (e.g., thyroid dysfunction, pituitary disorders)
Recommended tests: serum prolactin, thyroid function tests, imaging if indicated 1Management
First-line treatment: Bromocriptine (initial dose typically 1.25-2.5 mg daily, titrated up to 7.5-15 mg/day)
Response: 42 out of 50 patients ovulated, with 36 conceiving within 8 months
Side effects: Transient constipation, nausea
Monitoring: Regular assessment of prolactin levels, menstrual status, and pregnancy outcomes 1Special Populations
Pregnancy: Bromocriptine can induce ovulation and support conception; no congenital malformations noted in 29 newborns 1
Postpartum: Return to pretreatment status post-delivery indicates temporary nature of bromocriptine's effect 1Key Recommendations
Initiate bromocriptine for women with postpartum amenorrhea-galactorrhea to induce ovulation and restore menstruation (Evidence: Strong 1)
Monitor prolactin levels and menstrual status regularly during bromocriptine therapy (Evidence: Moderate 1)
Consider bromocriptine safe for conception, with no observed congenital malformations in treated cases (Evidence: Moderate 1)References
1 Zárate A, Canales ES, Forsbach G, Fernández-Lazala R. Bromocriptine. Clinical experience in the induction of pregnancy in amenorrhea-galactorrhea syndrome. Obstetrics and gynecology 1978. link